Bristol-Myers Squibb Company (BMY)
Healthcare · end-of-day data as of Oct 16, 2026
The average 12-month analyst price target for BMY is $65.38, 9.4% above the last close of $59.75 on Oct 16, 2026; targets range from $41.00 to $81.00. Rating consensus: Hold.
Snapshot
- P/E13.2x
- P/E vs sector-53.3%
- P/E vs own-13.2%
- Target upside+9.4%
- ConsensusHold
- Market cap$122B
- FCF yield+9.4%
- Insiders-$437K
- Earnings in13d
- News
Why it moved
Bristol-Myers Squibb Company (BMY) fell 1.4% on Oct 16, 2026.
The market (SPY) fell 1.1%; Healthcare stocks fell 0.7%. Most of the move came from the market as a whole.
2 stories on the day (30-day average 2.2).
- Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know
- Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.
Price and events
Last close $59.75 · +43.8% over 1y · E earnings · D dividend · S split · A analyst rating change
Technicals
- Trendbullish
- Sector▲ +16.0%
- MAs20▼ 50▼ 100▼ 200▲
- Above MAs1 of 4 above
- MA20×50—
- RSI45
- Support-2.0%
- Resistance+1.0%
- Off 52w high-11.3%
- Off ATH-12.1%
- 52w range$59.75
- Bollingerlower half
- MACD0.05
- ATR+3.0%
- Volume1.0x
Analyst price targets
16 firms with a target in the last 12 months · last close $59.75 · as of Oct 16, 2026
Strong buy 4 · Buy 7 · Hold 18 · Sell 1 · Strong sell 0
Revenue and free cash flow
Q2 FY2026: Revenue +5.7% year over year, free cash flow 23.8% of revenue, operating margin 31.0%.
| Q2 FY2026 | Jun 30, 2026 | $12.97B | 1.62 | $3.09B | 71.3% | 31.0% | 25.6% |
| Q1 FY2026 | Mar 31, 2026 | $11.49B | 1.31 | $757M | 70.2% | 29.3% | 23.3% |
| Q4 FY2025 | Dec 31, 2025 | $12.5B | 0.53 | $1.6B | 67.2% | 22.5% | 8.7% |
| Q3 FY2025 | Sep 30, 2025 | $12.22B | 1.08 | $5.99B | 71.9% | 29.8% | 18.0% |
| Q2 FY2025 | Jun 30, 2025 | $12.27B | 0.64 | $3.56B | 72.5% | 30.8% | 10.7% |
| Q1 FY2025 | Mar 31, 2025 | $11.2B | 1.20 | $1.69B | 72.9% | 31.2% | 21.9% |
| Q4 FY2024 | Dec 31, 2024 | $12.34B | 0.04 | $4.06B | 61.0% | 4.1% | 0.6% |
| Q3 FY2024 | Sep 30, 2024 | $11.89B | 0.60 | $5.27B | 75.1% | 18.3% | 10.2% |
Peers
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 |  | $255.56 | +0.9% | -8.2% | +8.8% | 38.7 | $616B | |
| 2 |  | $285.42 | +0.7% | 0.0% | -1.4% | 80.4 | $504B | |
| 3 |  | $145.95 | +0.5% | -6.2% | +7.7% | 116.8 | $360B | |
| 4 |  | $432.49 | -0.4% | -2.6% | -7.5% | 26.9 | $234B | |
| 5 |  | $156.19 | -0.7% | -0.7% | +1.9% | — | $194B | |
| 6 |  | $29.58 | +0.5% | 0.0% | -7.1% | 39.1 | $169B | |
| 7 | | $59.75 | -1.4% | -11.3% | +9.4% | 13.2 | $122B | |
| 8 |  | $232.65 | -1.1% | -1.1% | +2.7% | 41.2 | $34.37B |
Data as of Oct 16, 2026 close.
Latest news
Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.